首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1532527

尿病治療市場- 依治療類型（藥物[抗生素、α-受體阻斷劑]、引流裝置[導管、輸尿管支架]、手術程序）、年齡層（20歲以下、21-40歲、41-60歲、61-80歲）、結束-user - 全球預測（2024 - 2032）

Uropathy Treatment Market - By Treatment Type (Medication [Antibiotics, Alpha-blockers], Drainage Devices [Catheter, Ureteral Stents], Surgical Procedure), Age Group (Below 20, 21 - 40, 41 - 60, 61 - 80), End-user - Global Forecast (2024 - 2032)

出版日期: 2024年05月22日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在醫療支出增加和獲得先進治療的機會增加的推動下，2024 年至 2032 年全球尿路病治療市場的複合年成長率將達到 4.1%。根據世界衛生組織報告，2022年全球醫療保健支出將達到約8.6兆美元，預計年增率為5.4%。政府和私人實體資金的增加促進了醫療研發，從而帶來更好的診斷工具和治療選擇。改善的醫療基礎設施能夠更早發現並有效管理泌尿系統疾病，滿足日益成長的泌尿系統疾病照護需求。

泌尿系統疾病（例如泌尿道感染、腎結石和膀胱控制問題）的盛行率不斷上升，特別是在老年人口中，顯著增加了對有效治療的需求。診斷工具和治療方案的技術進步，包括微創手術技術、創新藥物療法和先進的醫療設備，正在改善患者的治療效果並擴大治療的可能性。

尿路病治療市場根據治療類型、年齡層、最終用戶和地區進行分類。

由於人們對泌尿系統疾病的認知提高和早期診斷，到 2032 年，藥物領域的複合年成長率將達到顯著水準。患者和醫療保健提供者正在尋求有效的藥物選擇來管理這些病症。重點是個人化醫療和更好的治療結果。藥物開發的創新和治療方法的增加，以及公眾認知度的提高，將推動對泌尿道病藥物的需求。

由於壓力水平和生活方式因素增加，導致泌尿系統疾病盛行率上升，到 2032 年，21-40 歲年齡層將獲得強大的泌尿系統疾病治療市場佔有率。此外，更高的健康意識和積極主動的醫療保健方法會導致更頻繁的診斷和治療。數位健康工具和遠距醫療在年輕人中的廣泛使用也使泌尿科諮詢和治療變得更加容易。此外，生育年齡和相關泌尿系統健康問題（例如生育問題和性傳染感染）在這群人中普遍存在，進一步推動了對專門泌尿道疾病治療的需求。

在醫療保健普及和泌尿系統疾病盛行率上升的支持下，北美泌尿道治療市場在預測期內將錄得顯著的複合年成長率。健康保險的覆蓋和先進的醫療設施導致更多的人尋求診斷和治療。對健康最佳化的高認知水準和重視加強了預防性護理和早期干預，從而增加了對綜合尿路病解決方案的需求。包括可支配收入增加在內的社會經濟因素將進一步推動北美的產業發展軌跡。

產業生態系統分析
產業影響力
- 成長動力
  - 泌尿系統疾病盛行率增加
  - 人們越來越偏好微創手術
  - 導管和支架的技術進步
- 產業陷阱與挑戰
  - 支架和導管導致感染和不適的風險
監管環境
管道分析
未來市場趨勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

主要趨勢
藥物
- 抗生素
- α-阻斷劑或α-還原酶抑制劑
- 其他藥物
排水裝置
- 導管
  - 留置導管
  - 間歇導管
  - 恥骨上導管
- 輸尿管支架
手術過程
其他治療類型

第 6 章：市場估計與預測：按年齡分類，2021 - 2032

主要趨勢
20歲以下
21 - 40
41 - 60
61 - 80

第 7 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

主要趨勢
醫院
門診手術中心
專科診所
其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Astellas Pharma Inc.
B. Braun Melsungen AG
Becton, Dickinson, and Company
Boston Scientific Corporation
Cook Medical
Glaxo SmithKline Pharmaceuticals Ltd.
Inceler Medikal Co. Ltd.
KARL STORZ
Purdue Pharma
Olympus America
Pfizer Inc.
Sun Pharmaceutical Industries Europe B.V.
Synthon BV
Teleflex Incorporated.
UROMED Kurt Drews KG

簡介目錄

Product Code: 9581

Global Uropathy Treatment Market will exhibit 4.1% CAGR from 2024 to 2032, thrusted by increasing healthcare expenditure and enhancing access to advanced treatments. According to the WHO reports, global healthcare spending reached approximately 8.6 trillion in 2022, with a projected annual growth rate of 5.4%. The rise in funding from governments and private entities facilitates medical R&D, leading to better diagnostic tools and treatment options. The improved medical infrastructure enables earlier detection and effective management of urological disorders, meeting the rising demand for uropathy care.

The rising prevalence of urological disorders, such as urinary tract infections, kidney stones, and bladder control issues, particularly among the aging population, is significantly increasing the demand for effective treatments. Technological advancements in diagnostic tools and treatment options, including minimally invasive surgical techniques, innovative drug therapies, and advanced medical devices, are improving patient outcomes and expanding treatment possibilities.

The uropathy treatment market is categorized based on treatment type, age group, end-user, and region.

The medications segment will register a noteworthy CAGR through 2032, owing to increased awareness and early diagnosis of urological disorders. Patients and healthcare providers are seeking effective pharmacological options for managing these conditions. There is focus on personalized medicine and better treatment outcomes. Innovations in drug development and greater availability of treatments, with improved cognizance amongst public, will propel the demand for uropathy medications.

The 21-40 years age segment will attain a strong uropathy treatment market share by 2032, due to increased stress levels and lifestyle factors, leading to rising prevalence of urological conditions. Additionally, greater health awareness and proactive healthcare approaches lead to more frequent diagnoses and treatments. The widespread use of digital health tools and telemedicine among younger adults is also facilitating easier access to urological consultations and treatments. Additionally, the reproductive age and associated urological health concerns, such as fertility issues and sexually transmitted infections, are prevalent in this group, further driving the need for specialized uropathy treatments.

North America uropathy treatment market will record a remarkable CAGR during the forecast period, backed by the increasing healthcare access and rising prevalence of urological conditions. The presence of health insurance coverage and advanced medical facilities lead to more individuals seeking diagnosis and treatment. The high awareness levels and emphasis on health optimization augment preventative care and early intervention, boosting the demand for comprehensive uropathy solutions. Socioeconomic factors, including higher disposable incomes, will further catalyze the industry trajectory in North America.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of urological disorders
  - 3.2.1.2 Growing preference for minimally invasive procedures
  - 3.2.1.3 Technological advancements in catheters and stents
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Risk of infection and discomfort due to stents and catheters
3.3 Regulatory landscape
3.4 Pipeline analysis
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Medication
- 5.2.1 Antibiotics
- 5.2.2 Alpha-blockers or alpha-reductase inhibitors
- 5.2.3 Other medication
5.3 Drainage devices
- 5.3.1 Catheters
  - 5.3.1.1 Indwelling catheters
  - 5.3.1.2 Intermittent catheter
  - 5.3.1.3 Suprapubic catheter
- 5.3.2 Ureteral stents
5.4 Surgical procedure
5.5 Other treatment types

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Below 20
6.3 21 - 40
6.4 41 - 60
6.5 61 - 80

Chapter 7 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Ambulatory surgical centers
7.4 Specialty clinics
7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 The Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa